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Abstract
Aims We sought to examine sex differences in congestion in patients hospitalized for acute heart failure (AHF). Understand-
ing congestive patterns in women and men with AHF may provide insights into sex differences in the presentation and
prognosis of AHF patients.
Methods and results In a prospective, two-site study in adults hospitalized for AHF, four-zone lung ultrasound (LUS) was
performed at the time of echocardiography at baseline (LUS1) and, in a subset, pre-discharge (LUS2). B-lines on LUS and
echocardiographic images were analysed offline, blinded to clinical information and outcomes. Among 349 patients with
LUS1 data (median age 74, 59% male, and 87% White), women had higher left ventricular ejection fraction (mean 43% vs.
36%, P < 0.001), higher tricuspid annular plane systolic excursion (mean 17 vs. 15 mm, P = 0.021), and higher measures of
filling pressures (median E/e′ 20 vs. 16, P < 0.001). B-line number on LUS1 (median 6 vs. 6, P = 0.69) and admission N-terminal
pro-B-type natriuretic peptide levels (median 3932 vs. 3483 pg/mL, P = 0.77) were similar in women and men. In 121 patients
with both LUS1 and LUS2 data, there was a similar and significant decrease in B-lines from baseline to discharge in both
women and men. The risk of the composite 90 day outcome increased with higher B-line number on four-zone LUS2:
unadjusted hazard ratio for each B-line tertile was 1.86 (95% confidence interval 1.08–3.20, P = 0.025) in women and 1.65
(95% confidence interval 1.03–2.64, P = 0.037) in men (interaction P = 0.72).
Conclusions Among patients with AHF, echocardiographic markers differed between women and men at baseline, whereas
B-line number on LUS did not. The dynamic changes in B-lines during a hospitalization for AHF were similar in women and
men.
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Introduction
Several sex differences have been reported in patients with
heart failure (HF) with respect to clinical presentation, risk
factors, pathophysiology, and prognosis.1 Although these
important sex differences have been previously investigated
in patients with HF, little is known about the sex differences
in pulmonary congestion on lung ultrasound (LUS) in patients
with HF. Congestion, particularly pulmonary congestion, is a
cardinal finding in patients with HF affecting the presentation
and prognosis of these patients. Based on data from ADHERE
and PROTECT, women with acute HF (AHF) demonstrate
more pronounced pulmonary congestion at baseline with a
higher prevalence of dyspnoea,2 orthopnoea,3 and rales.2,3
Although the differences are subtle in the ADHERE registry,
it is conceivable that LUS findings as a more sensitive
measure of pulmonary congestion in AHF may also differ
between women and men.
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Understanding the congestive patterns in women and men
may provide insights into the differences in presentation and
prognosis and thus aid in better patient management and risk
stratification. We, therefore, sought to investigate the sex
differences in congestive markers based on the physical ex-
amination, chest X-ray (CXR), echocardiography, laboratory
tests, and LUS in patients hospitalized for AHF. A secondary
aim was to examine the dynamic changes of congestive
markers during a hospitalization for AHF and in exploratory
analyses the prognostic value of these markers at discharge.
Methods
Study population
This is a post hoc analysis of a prospective, two-centre obser-
vational study in adult patients hospitalized for AHF at two
academic hospitals in Boston (USA) and in Glasgow (UK).
Details regarding the study population have previously been
described.4 Briefly, patients were enrolled from inpatient
units (both sites) and emergency department observation
units (Boston) if they were admitted with a diagnosis of
AHF (presenting with HF signs and symptoms and requiring
intravenous diuretics irrespective of ejection fraction). Pa-
tients were excluded from this study if they presented with
important lung diseases potentially affecting LUS findings
(e.g. pulmonary fibrosis and pneumonia), isolated right HF,
pregnancy, B-type natriuretic peptide <100 pg/mL in
Glasgow and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) <1400 pg/mL in Boston, or current dialysis.
Lastly, for this analysis, only patients who had an LUS
performed at baseline (LUS1) were included (Supporting
Information, Figure S1). LUS and echocardiography were
performed early during hospitalization within a median of
1 day after admission in both Glasgow (interquartile range
1–2 days) and Boston (inter-quartile range 1–1 day). Patients
gave written informed consent prior to participation. This
study complied with the Declaration of Helsinki and was ap-
proved by the local institutional review boards (Partners IRB
and the West of Scotland Research Ethics Service). The first
and senior authors had full access to all the data in the study
and take responsibility for its integrity and the data analysis.
Congestive markers
Lung ultrasonography protocol and image analysis
Lung ultrasound examinations were performed by trained in-
vestigators using conventional echocardiographic equipment
with a phased array transducer at baseline (LUS1) and in a
subset at discharge (LUS2). A simplified four-zone imaging
protocol was used for LUS assessment at both sites, and in
addition, an eight-zone LUS examination was performed in
Boston. The LUS images were analysed offline by experienced
investigators blinded to clinical data, timing of LUS, and out-
comes as previously described.4 The sum of the maximum
number of B-lines from each zone was used to obtain the to-
tal number of B-lines for each patient. With regard to the
intra-reader and inter-reader agreement, the mean B-line
difference in 25 patients for the four-zone LUS image analysis
was 0.4 (95% limits of agreement 1.1, 2.0) and 1.1 (95%
limits of agreement 2.2, 4.6) in Bland–Altman analyses,
respectively.4
Assessment of pleural effusions
The assessment of pleural effusion was performed at baseline
and discharge using the same equipment as for the LUS
examination with the transducer positioned laterally at the
level of the diaphragm on each hemithorax with patients in
a semi-recumbent position as previously described.5 The
presence of pleural effusions was quantified for each
hemithorax using the semi-quantitative pleural effusion score
ranging from 0 to 4 points.5 The total pleural effusion score
for each patient was then calculated as the sum of the pleural
effusion score from each hemithorax with values ranging
from 0 to 8.
Echocardiography
All patients underwent a conventional echocardiographic
examination early during the hospitalization. Images were
acquired using conventional echocardiographic equipment
with phased array transducers. Images were analysed offline
following the American Society of Echocardiography
guidelines6 by trained investigators at each site who were
blinded to clinical data and long-term outcomes. Left ventric-
ular ejection fraction (LVEF) was obtained using Simpson’s bi-
plane method. HF with preserved ejection fraction (HFpEF)
was defined as LVEF ≥ 45%. Left ventricular mass index was
calculated using linear left ventricular measurements and
indexed to body surface area. Left atrial volume index was
calculated using the area–length method and indexed to
body surface area. Peak velocity of early (E) and late (A) dia-
stolic filling was measured with pulsed-wave Doppler in the
apical four-chamber view with the sample volume placed be-
tween the mitral leaflet tips, and the E/A ratio was calculated.
Tissue Doppler imaging was used to obtain the average annu-
lar mitral peak early diastolic velocity (e′) from the lateral and
septal e′ values, and the E/e′ ratio was calculated from the av-
erage lateral and septal e′ measurements. Tricuspid annular
plane systolic excursion (TAPSE) was measured by M-mode
tracings of the tricuspid annulus from an apical
four-chamber view focused on the right ventricle (RV). Tricus-
pid regurgitation velocity was measured from the tricuspid
regurgitation jet using continuous-wave Doppler in the RV
apical four-chamber view. The estimated systolic pulmonary
artery pressure was calculated from the tricuspid regurgita-
tion velocity using the Bernoulli equation. Myocardial systolic
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excursion velocity, s′, was measured at the lateral tricuspid
annulus using tissue Doppler imaging in the apical
four-chamber view. The maximum inferior vena cava (IVC) di-
ameter was measured 1–2 cm proximal to the junction of the
IVC and the right atrium.6 The RV fractional area change was
calculated from the end-diastolic and end-systolic areas of
the RV in the apical four-chamber view.
Chest X-ray on admission
If clinically indicated, patients underwent an upright CXR ex-
amination on admission. These CXRs were analysed by radiol-
ogists for the presence of vascular congestion, interstitial
oedema, and alveolar oedema.5 Only CXR examinations
performed within 1 day of admission based on date change
were included in this analysis.
Physical examination, biochemical tests, and clinical and
demographic data
Laboratory tests were performed at baseline at both sites,
and clinical and demographic data were collected from med-
ical records by trained investigators at each site. Dyspnoea
assessments were completed by each patient at the time of
LUS1 and LUS2 based on a numerical ranking scale ranging
from 0 to 10 with 0 corresponding to no dyspnoea while lying
flat and 10 corresponding to severe dyspnoea at rest.7,8
Outcomes
The endpoint was time-to-first event of the composite out-
come of HF readmission or all-cause mortality at 90 days af-
ter discharge. Because of a differential association of B-lines
and the outcome over time, in which the relationship
between B-lines and the primary outcome was strongest
early after discharge and attenuated over time, we chose to
analyse the outcome at 90 days.4 HF hospitalizations were
adjudicated by experienced physicians at each site and
verified through patient follow-up phone calls, contacting
primary care physicians or cardiologists, and review of
electronic medical records. All-cause mortality was confirmed
through review of electronic medical records at both sites
and review of social security index and obituaries in Boston.
We assessed the outcomes in patients with an available
LUS2 (n = 132). As a sensitivity analysis, we also examined
outcomes in the LUS1 cohort (n = 339). Ten patients were ex-
cluded from the LUS1 cohort in the outcome analysis as they
died or had a left ventricular assist device implanted during
the initial hospital stay (CONSORT diagram, Supporting Infor-
mation, Figure S1).
Statistical analyses
Baseline characteristics and congestive markers were
summarized in women and men. Categorical variables were
compared using the χ2 test or Fisher’s exact test as appropri-
ate. Continuous variables were compared using Student’s
t-test or Wilcoxon rank-sum test as appropriate. We investi-
gated the correlation between the number of B-lines on
four-zone LUS1 and the log NT-proBNP levels using
Spearman’s correlation coefficient.
Dynamic changes in congestive markers from baseline to
pre-discharge were analysed using Student’s paired t-test or
Wilcoxon signed-rank test for comparing paired continuous
observations as appropriate. McNemar’s test and McNemar’s
exact test were used to compare paired categorical observa-
tions from baseline to pre-discharge as appropriate. To
compare the difference in the change in continuous markers
between women and men, we used Student’s t-test and
Wilcoxon rank-sum test.
Unadjusted and adjusted Cox proportional hazards models
were used to assess the risk of the composite endpoint of
rehospitalization for HF or all-cause mortality in women vs.
men. In Model 1, we adjusted for age, LVEF, baseline log
creatinine, and baseline systolic blood pressure, stratified by
study site. In Model 2, we adjusted for the same variables,
but instead of LVEF, we included log NT-proBNP and stratified
by study site. To further analyse possible predictors of the
90 day composite outcome in women and men separately,
unadjusted Cox proportional hazards model was used to
investigate the prognostic value of available congestive
markers at discharge on the 90 day composite outcome.
Results of these analyses were considered exploratory and
hypothesis generating. The proportional hazards assumptions
were assessed using Schoenfeld residuals, and interaction be-
tween sex and each covariate in the model was also checked.
Lastly, in order to examine whether the baseline or discharge
congestive marker was the most important predictor of the
composite outcome independent of sex, we included both
the baseline and corresponding discharge congestive marker
in the same model adjusted for sex. Statistical analyses were
performed using Stata SE, Version 14.1 (StataCorp., College
Station, TX, USA, 2015), and a two-sided P-value < 0.05 was
considered statistically significant.
Results
Baseline demographic and clinical parameters in
women and men
Of 370 eligible patients, 349 patients had an LUS examination
performed at baseline (LUS1) and were thus included in this
analysis (Glasgow n = 157; Boston n = 192). In this patient
cohort, there were 144 (41%) female patients. Baseline char-
acteristics of women and men are outlined in Table 1. Over-
all, women were older and had a lower body mass index
and higher systolic blood pressure. Women more often had
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HFpEF compared with men. Men were more likely to have a
history of prior HF, HF hospitalizations, and coronary heart
disease, whereas women were more likely to have a history
of depression. At baseline, men were more often treated
with beta-blockers and diuretics.
Baseline congestive markers
Findings related to congestion are outlined in Table 2.
Women reported significantly more severe dyspnoea than
men at baseline (median score 5 vs. 3, P < 0.001). On
physical examination, men were more likely than women
to present with lower extremity oedema on admission
(P = 0.011). There were also significant sex differences in
the echocardiographic measures. Overall, women had a
better left and right systolic function with a higher LVEF
(mean 43% vs. 36%, P < 0.001) and higher TAPSE (mean
17 vs. 15 mm, P = 0.021) and RV fractional area change
(mean 26% vs. 22%, P = 0.012), but greater measures of
filling pressures (E/e′ ratio median 19.5 vs. 15.8,
P < 0.001) and higher tricuspid regurgitation velocity
(mean 2.98 vs. 2.84 m/s, P = 0.039) than men. By contrast,
men had a higher E/A ratio (mean 2.12 vs. 1.46, P < 0.001)
and a greater maximum IVC diameter (2.3 vs. 2.1 cm,
P < 0.001). The distribution of pleural effusion scores in
tertiles on LUS was significantly different between women
and men, with women presenting with higher pleural
effusion scores, although the median pleural effusion score
was not significantly different between women and men.
The median number of B-lines and the distribution of
B-lines in tertiles on LUS1 were not significantly different
between women and men. These findings were similar in
HFpEF (n = 124) and HF with reduced ejection fraction
Table 1 Baseline characteristics of women and men (n = 349)
n Women (n = 144) Men (n = 205) P
Demographics
Age (years) 349 76 [70, 83] 73 [64, 81] 0.011
Hispanic, n (%) 191 6 (8%) 5 (4%) 0.34
Non-Hispanic, White, n (%) 349 120 (83%) 183 (89%) 0.11
Non-Hispanic, Black, n (%) 349 17 (12%) 15 (7%) 0.15
Clinical characteristics
BMI (kg/m2) 345 26 [22, 31] 28 [24, 32] 0.018
Heart rate (b.p.m.) 347 85 ± 22 81 ± 21 0.10
Systolic blood pressure (mmHg) 347 134 ± 28 125 ± 26 0.004
Diastolic blood pressure (mmHg) 346 72 ± 16 70 ± 16 0.31
NYHA functional class 349 0.07
I and II 33 (23%) 70 (34%)
III 83 (58%) 97 (47%)
IV 28 (19%) 38 (19%)
HFpEF (LVEF ≥ 45%), n (%) 349 67 (47%) 57 (28%) <0.001
Medical history
Prior HF, n (%) 349 74 (51%) 144 (70%) <0.001
Prior HF hospitalization, n (%) 349 49 (34%) 103 (50%) 0.003
Hypertension, n (%) 349 117 (81%) 153 (75%) 0.15
Diabetes, n (%) 349 48 (33%) 83 (40%) 0.17
Atrial fibrillation/flutter, n (%) 349 71 (49%) 121 (59%) 0.07
COPD, n (%) 349 32 (22%) 37 (18%) 0.34
PCI, n (%) 349 22 (15%) 50 (24%) 0.038
CABG, n (%) 349 19 (13%) 61 (30%) <0.001
Myocardial infarction, n (%) 349 39 (27%) 86 (42%) 0.004
Pacemaker, n (%) 349 17 (12%) 32 (16%) 0.22
CRT, n (%) 349 6 (4%) 19 (9%) 0.07
Depression, n (%) 347 28 (20%) 24 (12%) 0.045
Home medications
Beta-blockers, n (%) 349 95 (66%) 156 (76%) 0.038
ACE inhibitor/ARB, n (%) 349 67 (47%) 103 (50%) 0.49
ARNI, n (%) 192 2 (3%) 2 (2%) 0.63
Aldosterone blocker, n (%) 349 13 (9%) 31 (15%) 0.09
Diuretic(s), n (%) 349 83 (58%) 143 (70%) 0.02
Digoxin, n (%) 349 15 (10%) 16 (8%) 0.40
Calcium channel blockers, n (%) 349 39 (27%) 39 (19%) 0.08
Amiodarone, n (%) 197 8 (11%) 19 (16%) 0.40
Insulin, n (%) 349 23 (16%) 40 (20%) 0.56
Anticoagulation, n (%) 349 53 (37%) 91 (44%) 0.16
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BMI, body mass
index; b.p.m., beats per minute; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CRT, cardiac
resynchronization therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LVEF, left ventricular ejection fraction;
NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
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(n = 225). The laboratory tests revealed better renal func-
tion in women compared with men. The NT-proBNP levels
were not significantly different between women and men,
and there was a similar, although weak, positive correlation
between log (NT-proBNP) levels and number of B-lines on
four-zone LUS1 in both women and men (r = 0.36,
P < 0.001 and r = 0.23, P = 0.002, respectively) (Supporting
Information, Figure S2).
Table 2 Congestive markers and length of hospital stay in women and men (n = 349)
n Women (n = 144) Men (n = 205) P
Dyspnoea score (range 0–10; 10 worst)
Dyspnoea at rest 190 5 [3, 8] 3 [0, 7] <0.001
Baseline laboratory results
NT-proBNP (pg/mL) 316 3483 [1841, 7971] 3932 [1794, 7927] 0.77
Sodium (mmol/L) 349 138 [135, 141] 138 [136, 140] 0.45
Potassium (mmol/L) 346 4.21 ± 0.60 4.26 ± 0.62 0.37
Haemoglobin (g/dL) 349 11.5 ± 1.9 11.9 ± 2.3 0.09
BUN (mg/dL) 349 22 [17, 33] 28 [21, 50] <0.001
Creatinine (mg/dL) 349 1.1 [0.8, 1.5] 1.4 [1.1, 2.1] <0.001
Albumin (g/dL) 320 3.45 ± 0.48 3.51 ± 0.46 0.22
Baseline CXRa
Vascular congestion, n (%) 138 42 (71%) 55 (70%) 0.84
Interstitial oedema, n (%) 139 52 (87%) 62 (78%) 0.27
Alveolar oedema, n (%) 139 9 (15%) 9 (11%) 0.61
Echocardiography
LVEF (%) 349 43 ± 16 36 ± 15 <0.001
LVMI (g/m2) 318 113 ± 34 128 ± 41 0.005
LAVI (mL/m2) 335 47 [33, 63] 44 [36, 56] 0.66
E (m/s) 299 1.14 ± 0.35 1.03 ± 0.31 0.004
A (m/s) 176 0.77 [0.53, 1.01] 0.49 [0.36, 0.72] <0.001
E/A 173 1.46 [0.92, 2.10] 2.12 [1.40, 2.83] <0.001
e′, cm/s (average) 297 0.06 ± 0.02 0.06 ± 0.02 0.025
E/e′ (average) 286 19.5 [15.2, 26.3] 15.8 [12.9, 20.5] <0.001
TAPSE (mm) 285 17 ± 6 15 ± 6 0.021
TR velocity (m/s) 317 2.98 ± 0.63 2.84 ± 0.57 0.039
s′ (cm/s) 329 0.07 [0.05, 0.10] 0.08 [0.05, 0.10] 0.16
IVC max (cm) 300 2.1 ± 0.54 2.3 ± 0.52 <0.001
Estimated systolic PA pressure (mmHg) 170 47 ± 18 45 ± 15 0.57
RV fractional area change (%) 157 26 ± 10 22 ± 9 0.012
Physical examination
Weight (kg) 345 66 [57, 80] 84 [74, 98] <0.001
SpO2 (%) 346 96 [95, 98] 97 [95, 98] 0.26
Supplemental O2, n (%) 344 47 (33%) 51 (25%) 0.11
Jugular venous distension (>10 cm), n (%) 177 45 (70%) 91 (81%) 0.12
Crackles on auscultation, n (%) 349 101 (70%) 125 (61%) 0.08
Lower extremity oedema, n (%) 349 98 (68%) 164 (80%) 0.011
S3, n (%) 347 25 (18%) 30 (15%) 0.49
LUS1
Number of B-lines, 4 zones (tertiles), n (%) 349 0.96
0–4 B-lines 51 (35%) 70 (34%)
5–9 B-lines 54 (38%) 77 (38%)
≥10 B-lines 39 (27%) 58 (28%)
B-line count, 4 zones 349 6 [3, 10] 6 [3, 10] 0.69
Number of B-lines, 8 zones (tertiles), n (%) 192 0.24
0–5 B-lines 17 (23%) 29 (25%)
6–11 B-lines 25 (34%) 27 (23%)
≥12 B-lines 32 (43%) 62 (53%)
B-line count, 8 zones, n (%) 192 10 [6, 16] 12 [6, 19] 0.13
Pleural effusion score (tertiles), n (%) 178 0.048
0 15 (23%) 42 (37%)
1–4 27 (42%) 29 (25%)
5–8 22 (34%) 43 (38%)
Pleural effusion score 178 2 [1, 6] 2 [0, 6] 0.29
Length of stay (days) 349 6 [3, 13] 7 [3, 12] 0.95
A, late mitral inflow velocity; BUN, blood urea nitrogen; CXR, chest X-ray; E, early mitral inflow velocity; E/A, ratio between early mitral
inflow velocity and late mitral inflow velocity; E/e′, ratio between early mitral inflow velocity and mitral annular early diastolic velocity;
e′, mitral annular early diastolic velocity; IVC, inferior vena cava; LAVI, left atrial volume index; LUS1, lung ultrasound at baseline; LVEF,
left ventricular ejection fraction; LVMI, left ventricular mass index; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PA, pulmonary
artery; RV, right ventricle; s′, myocardial systolic excursion velocity; S3, third heart sound; SpO2, blood oxygen level; supplemental O2, sup-
plemental oxygen; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.
aWithin 1 day of admission.
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Dynamic changes in congestive markers from
baseline to discharge
In 129 patients with both LUS1 and LUS2, the dyspnoea score
at rest, several physical examination parameters, blood urea
nitrogen values, and LUS findings differed significantly from
baseline to discharge in women and men (Table 3).
Although there were significant differences in these con-
gestive markers from baseline to discharge in women and
men separately, the change in the continuous congestive
markers from baseline to discharge was not significantly
different between women and men. However, while the pro-
portion of women with crackles on auscultation and lower
extremity oedema did not change significantly from baseline
to discharge, these proportions decreased significantly from
baseline to discharge in men (Figure 1). The change in
B-lines from both four-zone and eight-zone LUS from baseline
to discharge did not differ significantly between women and
men (Figure 2).
Ninety day outcomes in women and men
Considering the 132 patients who underwent a discharge LUS
examination (LUS2, n = 132), 17 (32.1%) women and 25
(31.6%) men experienced the composite outcome of
all-cause death or HF hospitalization during the 90 day
follow-up (P = 0.96) (Table 4). There were no significant dif-
ferences in 90 day outcomes between women and men with
available LUS2 data. In sensitivity analyses, we compared
event rates in the entire cohort of patients with LUS1 data
and the subset of patients with LUS2 data (Table 4). Among
the 339 patients with an LUS1 who were not censored prior
to hospital discharge, 37 (25.9%) women and 49 (25.0%)
men experienced the composite outcome over the 90 day
follow-up period (P = 0.86). There were also no significant dif-
ferences in 90 day HF hospitalization, all-cause death, or com-
posite outcome in women and men in the LUS1 cohort.
Predictors of 90 day outcomes and interaction
with sex
The risk of the composite 90 day outcome in women com-
pared with men was not significantly different in unadjusted
or adjusted models (Supporting Information, Table S1).
In an exploratory analysis, we investigated the predictive
value of discharge congestive parameters for the 90 day com-
posite outcome in women and men separately in univariable
analysis (Table 5). No significant violations of the propor-
tional hazards assumptions were detected. The risk of the
composite 90 day outcome increased with higher number
of B-lines on four-zone LUS2 in both women and men [unad-
justed hazard ratio (HR) for each B-line tertile in women 1.86,
95% confidence interval (CI) 1.08–3.20, P = 0.025 and in men
1.65, 95% CI 1.03–2.64, P = 0.037; interaction P = 0.72]. In
men, dyspnoea scores at rest (HR 1.17, 95% CI 1.01–1.36,
P = 0.032), blood urea nitrogen values (HR 1.02, 95% CI
1.00–1.03, P = 0.011), and number of B-lines on eight-zone
LUS2 (HR 1.72, 95% CI 1.01–2.92, P = 0.046) were also signif-
icantly associated with the risk of the composite 90 day out-
come in univariable analysis. None of the other available
congestive markers at discharge were significant predictors
of the 90 day composite outcome in women or men.
When including both the baseline LUS1 and the discharge
LUS2 from four-zone and eight-zone LUS in the same Cox
regression model, only the discharge LUS2 was a significant
predictor of outcomes when adjusting for sex (Supporting
Information, Table S2). Similarly, for the dyspnoea score at
rest, only the discharge score was a significant predictor of
outcome. However, for the other congestive markers, neither
the baseline nor the discharge markers were significant
predictors.
Discussion
In this prospective, two-centre study, we investigated sex dif-
ferences in congestive markers based on several diagnostic
examinations in patients hospitalized for AHF. Despite similar
radiological findings and NT-proBNP levels, women hospital-
ized for AHF were significantly more dyspnoeic than men
and had a substantially higher E/e′ than men at baseline.
Conversely, men more often had lower extremity oedema
and a higher maximum IVC diameter than women at base-
line. Despite this different presentation, the number of
B-lines on baseline LUS did not differ between women and
men. However, as expected, more women than men had
HFpEF (47% vs. 28%, P < 0.001).
Baseline congestive markers and dynamic
changes
Similar to prior studies in patients with AHF,2,3,9–14 women
were older and had higher systolic blood pressure in this
cohort. The baseline LUS findings were similar in women
and men and consistent with the baseline CXR findings, with
respect to the presence of vascular congestion, interstitial
oedema, or alveolar oedema, and, likewise, findings on lung
auscultation. Despite these consistent findings regarding pul-
monary congestion in both sexes, women reported worse
dyspnoea and had higher measures of filling pressures (E/e′)
at baseline. These findings could indicate differences in
haemodynamics between women and men with AHF and
highlight the non-specific nature of dyspnoea in this
disease state. Our findings indicate further that pulmonary
Sex differences in acute heart failure 1789
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congestion responds similarly to HF therapy during an AHF
hospitalization in both sexes as measured by the reduction
in B-lines on LUS. Furthermore, the correlation between
B-lines and log NT-proBNP levels in women and men was
similar and significant. These findings suggest that the preva-
lence and dynamic changes in LUS findings in women and
men with AHF are similar and that sex-specific cut-off values
may not be needed.
During the hospitalization, there was a similar and signifi-
cant decrease in the number of B-lines and pleural effusion
size from baseline to discharge in both women and men. Al-
though women were more dyspnoeic than men at baseline
with higher dyspnoea scores on a numeric ranking scale,
the decrease in dyspnoea score from baseline to discharge
was similar in women and men. However, whereas women
did not display a significant decrease in the proportion of
Figure 1 Dynamic changes in physical examination parameters and dyspnoea score from baseline to discharge (n = 121) in women (n = 46) and men
(n = 75). Dyspnoea score at rest divided into three categories: blue represents a score of 6-10, green represents a score of 3–5, and orange represents a
score of 0-2. For the physical examination parameters, blue represents presence of the particular physical examination parameter, and green repre-
sents absence of the particular physical examination parameter. JVD, jugular venous distension.
Figure 2 Dynamic changes in B-lines from baseline to discharge on the four-zone and eight-zone lung ultrasound (LUS) in women and men (n = 121).
Four-zone LUS: change in B-lines from baseline to discharge in women (n = 46), P = 0.014, and in men (n = 75), P < 0.001. Eight-zone LUS: change in
B-lines from baseline to discharge in women (n = 45), P < 0.001, and in men (n = 75), P < 0.001.
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patients with crackles on auscultation or lower extremity oe-
dema from baseline to discharge, men did. A higher propor-
tion of men had lower extremity oedema at baseline, which
may explain the difference in the dynamic changes in lower
extremity oedema during the hospitalization. Other conges-
tive markers examined in this study showed similar changes
from baseline to discharge in women and men.
Prior studies report differing congestive patterns in women
and men with AHF with regard to physical examination find-
ings and symptoms at baseline.2,3,9,10,12,14
In ADHERE and PROTECT, women with AHF demonstrated
more pronounced pulmonary congestion at baseline with a
higher prevalence of dyspnoea,2 orthopnoea,3 and rales,2,3
although these differences were subtle in the ADHERE regis-
try. By contrast, in the ALARM-HF registry and the RELAX-AHF
trial, there were no significant sex differences in measures
of pulmonary congestion based on dyspnoea, orthopnoea,
or rales at baseline between women and men.10,12 In our
cohort, LUS findings were similar in women and men, and
likewise, there were no significant differences in auscultation
findings despite the fact that women were more dyspnoeic.
Regarding the other physical exam parameters, prior AHF
trials and data from registries have reported heterogeneous
findings with respect to sex differences. While the higher
prevalence of peripheral oedema in men in the current study
was in line with results from the ADHERE registry,2 the
Table 4 Ninety day outcomes by sex in patients with LUS1 (n = 339) and patients with LUS2 (n = 132)
Outcome
LUS1 cohort (n = 339): 90 day outcomesa LUS2 cohort (n = 132): 90 day outcomes
Men (n = 196) Women (n = 143) P Men (n = 79) Women (n = 53) P
HF hospitalization 36 (18%) 32 (22%) 0.36 18 (23%) 14 (26%) 0.63
All-cause death 16 (8%) 11 (8%) 0.87 8 (10%) 5 (9%) 0.90
Composite 49 (25%) 37 (26%) 0.86 25 (32%) 17 (32%) 0.96
HF, heart failure; LUS1, lung ultrasound at baseline; LUS2, lung ultrasound at discharge.
aTen patients from the LUS1 cohort had in-hospital deaths or a left ventricular assist device implanted; therefore, they are excluded for the
outcome analysis.
Table 5 Predictors of composite outcome at 90 days using congestive markers at discharge (n = 132)
Variables
At 90 days (n = 132)
Women (n = 53) Men (n = 79) Interaction with sex
Unadjusted HR (95% CI) P HR (95% CI) P P
Dyspnoea score (range 0–10; 10 worst)
Dyspnoea at rest (per 1 score increase) 1.11 (0.97–1.28) 0.14 1.17 (1.01–1.36) 0.032 0.65
Physical exama
Weight (per 1 kg increase) 0.99 (0.97–1.01) 0.40 0.99 (0.97–1.01) 0.24 0.87
SpO2 (per 1% increase) 1.13 (0.91–1.39) 0.27 0.96 (0.79–1.17) 0.70 0.28
Supplemental O2 1.44 (0.41–5.06) 0.57 1.18 (0.28–5.01) 0.82 0.85
JVD > 10 cm 2.11 (0.47–9.46) 0.33 1.67 (0.57–4.90) 0.36 0.82
Crackles (any) 1.14 (0.43–3.04) 0.79 1.25 (0.55–2.84) 0.59 0.90
Lower extremity oedema (any) 0.51 (0.25–1.04) 0.07 1.41 (0.71–2.82) 0.33 0.98
Laboratory values
Sodium (per 1 mmol/L increase) 0.99 (0.86–1.15) 0.90 0.94 (0.84–1.04) 0.24 0.52
BUN (per 1 mg/dL increase) 1.01 (0.99–1.03) 0.60 1.02 (1.00–1.03) 0.011 0.42
Creatinine (per 1 mg/dL increase) 1.22 (0.68–2.17) 0.50 1.25 (0.97–1.60) 0.08 0.95
Lung ultrasound
Number of B-lines, 4 zones
(per tertile increase, trend)b
1.86 (1.08–3.20) 0.025 1.65 (1.03–2.64) 0.037 0.72
Number of B-lines, 8 zones
(per tertile increase, trend)c
1.64 (0.90–2.99) 0.11 1.72 (1.01–2.92) 0.046 0.95
Pleural effusion score at time of LUS2
(per tertile increase, trend)d
1.63 (0.86–3.12) 0.14 0.97 (0.57–1.65) 0.91 0.22
BUN, blood urea nitrogen; JVD, jugular venous distension; LUS2, lung ultrasound at discharge; SpO2, blood oxygen level; supplemental
O2, supplemental oxygen.
aS3 was not included in the outcome analysis, as there were too few measurements for women.
bB-line tertiles for four-zone LUS: 0–3, 4–6, and ≥7 B-lines.
cB-line tertiles for eight-zone LUS: 0–5, 6–11, and ≥12 B-lines.
dPleural effusion score tertiles; 0, 1–4, and 5–8.
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RELAX-AHF and PROTECT trials detected no significant sex dif-
ferences in the presence of peripheral oedema.3,12 However,
in the ALARM-HF registry, more women than men had
oedema at baseline,10 underscoring the heterogeneous find-
ings of congestion across the different AHF cohorts. The prev-
alence of jugular venous distension in women and men did
not differ significantly in the current study, matching the
results of ALARM-HF, RELAX-AHF, and PROTECT.3,10,12
In terms of the echocardiographic findings, women had
better left and right systolic function and higher measures
of filling pressures (E/e′). The differences in E/e′ despite sim-
ilar LUS findings may be explained by a slightly older age in
women compared with men in this study, as E/e′ increases
with age.15 Another potential explanation may be that
women had more impaired diastolic function with elevated
filling pressures and HFpEF, whereas men had more
biventricular systolic HF as indicated by a lower ejection frac-
tion and TAPSE compared with women. This is supported by
the larger proportion of men with a prior history of HF and
lower extremity oedema and a higher maximum IVC diameter
at baseline in men. The higher left ventricular filling pressures
(E/e′) in women compared with men in this study is in line
with the results of prior studies in both patients with HFpEF
and HF with reduced ejection fraction.16–18
Although previous studies have found that natriuretic
peptide levels are higher in women than in men in the gen-
eral population,19–21 we did not find a significant difference
in NT-proBNP levels between women and men with AHF at
baseline. Prior studies in hospitalized patients with AHF have
reported heterogeneous findings with respect to sex differ-
ences in natriuretic peptides.9,11,12,14,22–24 This could be
explained by differences in the proportion of patients with
atrial fibrillation and worsening renal function across these
studies among other factors.
Outcomes
In accordance with prior studies comparing long-term out-
comes of mortality and/or readmission in women and men
with AHF,9,13,14,22–24 we did not find a significant difference
in the risk of the 90 day composite outcome in women com-
pared with men in this study. We found that the risk of the
composite 90 day outcome increased with higher number of
B-lines on four-zone LUS2 in both women and men in an un-
adjusted, exploratory analysis, highlighting the importance
of monitoring and treating pulmonary congestion
properly prior to discharge in both women and men. There
was no significant interaction between sex and B-lines on
four-zone LUS. These associations suggest that pulmonary
congestion based on the number of B-lines on LUS has a
similar prognostic value in women and men. However, these
associations should be investigated further in larger, pro-
spective studies allowing for adjustment for important
clinical and demographic variables. There was no significant
interaction between sex and any of the examined conges-
tive markers at discharge, suggesting that subtle differences
between women and men could be due to a limited number
of observations and events and that the congestive markers
display an overall similar prognostic pattern in women and
men.
Interestingly, only B-lines on LUS2 but not LUS1 remained
important predictors of the composite outcome when both
were included in the same model adjusting for sex. Similarly,
for dyspnoea scores, only the discharge parameters were sig-
nificant predictors of outcomes. These findings highlight the
importance of pre-discharge assessment of congestion in
patients who are hospitalized for AHF both clinically and in
research.
Strengths and limitations
To the best of the authors’ knowledge, this is the first study
to specifically investigate sex differences in LUS findings in a
cohort of AHF patients. This study employed offline analysis
of all LUS videos, temporal blinding during image analysis,
and standardized endpoint adjudication. However, because
of the limited number of patients with pre-discharge ultra-
sound examinations, we were unable to conduct multivari-
able analyses of the predictors of the 90 day outcome in
women and men separately. Therefore, differences in the
prognostic importance of LUS findings between women and
men should be considered hypothesis generating and investi-
gated further in larger studies. Furthermore, patients did not
undergo a pre-discharge echocardiographic examination or
NT-proBNP measurements in the majority of cases, and
therefore, we could not investigate the dynamic changes in
these parameters from baseline to discharge or their associa-
tion with 90 day outcomes.
Conclusions
Among patients hospitalized for AHF, there were statistically
significant sex differences in the echocardiographic parame-
ters at baseline, whereas LUS findings, CXR findings, and
NT-proBNP levels did not differ significantly between women
and men. Furthermore, there was a similar and significant
decrease in the number of B-lines on LUS from baseline to
discharge in women and men. In an exploratory analysis,
the risk of the 90 day composite outcome increased signifi-
cantly with higher number of B-lines on four-zone LUS at
discharge in both women and men. These associations should
be investigated further in larger studies.
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